- Home
- DVAX vs ADEA Comparison
DVAX vs ADEA Comparison
Compare DVAX & ADEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DVAX | ADEA |
|---|---|---|
| Founded | 1996 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | DVAX | ADEA |
|---|---|---|
| Price | $15.39 | $17.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $26.50 | $21.00 |
| AVG Volume (30 Days) | ★ 3.3M | 965.7K |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | ★ 1.18% |
| EPS Growth | N/A | ★ 75.65 |
| EPS | N/A | ★ 0.65 |
| Revenue | $330,514,000.00 | ★ $379,912,000.00 |
| Revenue This Year | $24.63 | N/A |
| Revenue Next Year | $15.85 | $10.13 |
| P/E Ratio | ★ N/A | $26.06 |
| Revenue Growth | ★ 26.73 | 10.53 |
| 52 Week Low | $9.20 | $10.59 |
| 52 Week High | $15.49 | $18.25 |
Technical Indicators
Market Signals| Indicator | DVAX | ADEA |
|---|---|---|
| Relative Strength Index (RSI) | 89.00 | 72.91 |
| Support Level | $10.78 | $12.70 |
| Resistance Level | $15.49 | $18.12 |
| Average True Range (ATR) | 0.22 | 0.64 |
| MACD | 0.44 | 0.60 |
| Stochastic Oscillator | 97.74 | 80.30 |
Price Performance
Historical ComparisonAbout DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.